These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 37935773)
1. Real-time monitoring of the reaction of KRAS G12C mutant specific covalent inhibitor by in vitro and in-cell NMR spectroscopy. Zhao Q; Haga R; Tamura S; Shimada I; Nishida N Sci Rep; 2023 Nov; 13(1):19253. PubMed ID: 37935773 [TBL] [Abstract][Full Text] [Related]
2. Revealing the mechanism of action of a first-in-class covalent inhibitor of KRASG12C (ON) and other functional properties of oncogenic KRAS by Sharma AK; Pei J; Yang Y; Dyba M; Smith B; Rabara D; Larsen EK; Lightstone FC; Esposito D; Stephen AG; Wang B; Beltran PJ; Wallace E; Nissley DV; McCormick F; Maciag AE J Biol Chem; 2024 Feb; 300(2):105650. PubMed ID: 38237681 [TBL] [Abstract][Full Text] [Related]
4. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor. Janes MR; Zhang J; Li LS; Hansen R; Peters U; Guo X; Chen Y; Babbar A; Firdaus SJ; Darjania L; Feng J; Chen JH; Li S; Li S; Long YO; Thach C; Liu Y; Zarieh A; Ely T; Kucharski JM; Kessler LV; Wu T; Yu K; Wang Y; Yao Y; Deng X; Zarrinkar PP; Brehmer D; Dhanak D; Lorenzi MV; Hu-Lowe D; Patricelli MP; Ren P; Liu Y Cell; 2018 Jan; 172(3):578-589.e17. PubMed ID: 29373830 [TBL] [Abstract][Full Text] [Related]
5. Pharmacophoric analogs of sotorasib-entrapped KRAS G12C in its inactive GDP-bound conformation: covalent docking and molecular dynamics investigations. Oyedele AK; Ogunlana AT; Boyenle ID; Ibrahim NO; Gbadebo IO; Owolabi NA; Ayoola AM; Francis AC; Eyinade OH; Adelusi TI Mol Divers; 2023 Aug; 27(4):1795-1807. PubMed ID: 36271195 [TBL] [Abstract][Full Text] [Related]
6. The G protein signaling regulator RGS3 enhances the GTPase activity of KRAS. Li C; Vides A; Kim D; Xue JY; Zhao Y; Lito P Science; 2021 Oct; 374(6564):197-201. PubMed ID: 34618566 [TBL] [Abstract][Full Text] [Related]
7. Discovery of ARS-1620 analogs as KRas G12C inhibitors with high in vivo antitumor activity. Zhao H; Li L; Liu J; Mai R; Chen J; Chen J Bioorg Chem; 2022 Apr; 121():105652. PubMed ID: 35158284 [TBL] [Abstract][Full Text] [Related]
8. Assessment of KRAS G12C Target Engagement by a Covalent Inhibitor in Tumor Biopsies Using an Ultra-Sensitive Immunoaffinity 2D-LC-MS/MS Approach. Meng L; Chan EW; Ng C; Aimi J; Tran JC; Oh AJ; Merchant M; Purkey HE; Heffron TP; Kaur S; Xu K; Shi Z; He J Anal Chem; 2022 Sep; 94(37):12927-12933. PubMed ID: 36083155 [No Abstract] [Full Text] [Related]
9. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Lito P; Solomon M; Li LS; Hansen R; Rosen N Science; 2016 Feb; 351(6273):604-8. PubMed ID: 26841430 [TBL] [Abstract][Full Text] [Related]
10. [Pharmacological characteristics and clinical study results of the first RAS inhibitor sotorasib (LUMAKRAS Hoshiyama H Nihon Yakurigaku Zasshi; 2023; 158(5):391-398. PubMed ID: 37673617 [TBL] [Abstract][Full Text] [Related]
11. Development and Preclinical Evaluation of Radiolabeled Covalent G12C-Specific Inhibitors for Direct Imaging of the Oncogenic KRAS Mutant. Zhang Z; Wang X; Ye J; Liu H; Fang J; Zhang M; Li Y; Huang J; Zhang D; Wang J; Zhang X Mol Pharm; 2021 Sep; 18(9):3509-3518. PubMed ID: 34410132 [TBL] [Abstract][Full Text] [Related]
12. Covalent fragment mapping of KRas Orgován Z; Péczka N; Petri L; Ábrányi-Balogh P; Ranđelović I; Tóth S; Szakács G; Nyíri K; Vértessy B; Pálfy G; Vida I; Perczel A; Tóvári J; Keserű GM Eur J Med Chem; 2023 Mar; 250():115212. PubMed ID: 36842271 [TBL] [Abstract][Full Text] [Related]